Billion-dollar deal validates Zealand project
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7575834.ece/ALTERNATES/schema-16_9/Zealand%2520Pharma%2520forskning3.jpg)
Zealand Pharma has increased its focus on candidate drug ZP1848 to treat Short Bowel Syndrome and, according to Danske Bank’s healthcare analyst Thomas Bowers, that move makes sense in more than one way.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand CEO sees competitive advantage over Novo
For abonnenter
Zealand CEO: We are obligated to be ambitious
For abonnenter
Zealand chief is pleased with quiet quarter
For abonnenter